These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 23373648)
1. Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents. Negi A; Ramarao P; Kumar R Mini Rev Med Chem; 2013 Apr; 13(5):653-81. PubMed ID: 23373648 [TBL] [Abstract][Full Text] [Related]
2. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution. Jin M; Wang J; Buck E; Mulvihill MJ Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939 [TBL] [Abstract][Full Text] [Related]
3. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Singh P; Alex JM; Bast F Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270 [TBL] [Abstract][Full Text] [Related]
4. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment. You L; Liu C; Tang H; Liao Y; Fu S Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362 [TBL] [Abstract][Full Text] [Related]
5. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189 [TBL] [Abstract][Full Text] [Related]
6. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats. Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006 [TBL] [Abstract][Full Text] [Related]
8. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents. Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601 [TBL] [Abstract][Full Text] [Related]
9. Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells. Zovko A; Novak M; Hååg P; Kovalerchick D; Holmlund T; Färnegårdh K; Ilan M; Carmeli S; Lewensohn R; Viktorsson K Oncotarget; 2016 Aug; 7(31):50258-50276. PubMed ID: 27384680 [TBL] [Abstract][Full Text] [Related]
10. Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Miller LM; Mayer SC; Berger DM; Boschelli DH; Boschelli F; Di L; Du X; Dutia M; Floyd MB; Johnson M; Kenny CH; Krishnamurthy G; Moy F; Petusky S; Tkach D; Torres N; Wu B; Xu W Bioorg Med Chem Lett; 2009 Jan; 19(1):62-6. PubMed ID: 19041240 [TBL] [Abstract][Full Text] [Related]
11. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359 [TBL] [Abstract][Full Text] [Related]
12. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Ozkan EE Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884 [TBL] [Abstract][Full Text] [Related]
13. Crosstalk between IGF-1R and other tumor promoting pathways. Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361 [TBL] [Abstract][Full Text] [Related]
14. Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Paz K; Hadari YR Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543 [TBL] [Abstract][Full Text] [Related]
15. Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Mayer SC; Banker AL; Boschelli F; Di L; Johnson M; Kenny CH; Krishnamurthy G; Kutterer K; Moy F; Petusky S; Ravi M; Tkach D; Tsou HR; Xu W Bioorg Med Chem Lett; 2008 Jun; 18(12):3641-5. PubMed ID: 18501599 [TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Buck E; Mulvihill M Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886 [TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors. Buchanan JL; Newcomb JR; Carney DP; Chaffee SC; Chai L; Cupples R; Epstein LF; Gallant P; Gu Y; Harmange JC; Hodge K; Houk BE; Huang X; Jona J; Joseph S; Jun HT; Kumar R; Li C; Lu J; Menges T; Morrison MJ; Novak PM; van der Plas S; Radinsky R; Rose PE; Sawant S; Sun JR; Surapaneni S; Turci SM; Xu K; Yanez E; Zhao H; Zhu X Bioorg Med Chem Lett; 2011 Apr; 21(8):2394-9. PubMed ID: 21414779 [TBL] [Abstract][Full Text] [Related]